Does long-term metformin treatment increase cardiac lipoprotein lipase?

Hauton D

Metabolism: clinical and experimental12 Feb 2010Cited by 19 (Europe PMC)

PMID20153488PMCIDPMC3004047DOI10.1016/j.metabol.2009.12.015PepBankPUB-20153488

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueMechanism
In perfused rat hearts, AICAR increased labeled Intralipid uptake.
In plain wordsIn lab tests with rat hearts, AICAR increased uptake of labeled Intralipid.
Peptide
AICAR (acadesine)
Outcome
IncreaseIntralipid uptake
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
For perfused rat hearts, increased uptake of labeled Intralipid and β-oxidation of Intralipid-fatty acid were noted for both AICAR (P < .05) and high-dose metformin (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348801
02LabEx vivo tissueMechanism
In perfused rat hearts, AICAR increased beta-oxidation of Intralipid fatty acid.
In plain wordsIn lab tests with rat hearts, AICAR increased fatty acid breakdown.
Peptide
AICAR (acadesine)
Outcome
IncreaseIntralipid fatty acid beta-oxidation
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
For perfused rat hearts, increased uptake of labeled Intralipid and β-oxidation of Intralipid-fatty acid were noted for both AICAR (P < .05) and high-dose metformin (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348802
03LabEx vivo tissueMechanism
In perfused rat hearts, AICAR decreased Intralipid incorporation into tissue lipids.
In plain wordsIn lab tests with rat hearts, AICAR reduced Intralipid incorporation into tissue fats.
Peptide
AICAR (acadesine)
Outcome
DecreaseIntralipid incorporation into tissue lipids
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
Intralipid incorporation into tissue lipids was decreased by AICAR (P < .05) and increased after high-dose metformin (P < .05), the increase manifest as enhanced triacylglycerol deposition (P < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348803
04LabEx vivo tissueMechanism
In rat hearts, AICAR decreased cardiac acetyl-coenzyme A carboxylase activity.
In plain wordsIn lab tests with rat hearts, AICAR reduced acetyl-coenzyme A carboxylase activity.
Peptide
AICAR (acadesine)
Outcome
DecreaseAcetyl-coenzyme A carboxylase activity
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Receptor activity and mechanism · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
Both high-dose metformin and AICAR decreased cardiac acetyl-coenzyme A carboxylase activity (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348804
05LabEx vivo tissueMechanism
In rat hearts, AICAR increased heparin-releasable lipoprotein lipase.
In plain wordsIn lab tests with rat hearts, AICAR increased lipoprotein lipase released by heparin.
Peptide
AICAR (acadesine)
Outcome
IncreaseHeparin-releasable lipoprotein lipase
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
Heparin-releasable LPL was increased after treatment with AICAR (P < .05) and high-dose metformin (P < .01).
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348805
06LabEx vivo tissueMechanism
In rat hearts pretreated with heparin, AICAR increased lipoprotein lipase recruitment to cardiac endothelium.
In plain wordsIn lab tests with rat hearts, AICAR increased lipoprotein lipase recruitment to blood vessel linings after heparin pretreatment.
Peptide
AICAR (acadesine)
Outcome
IncreaseLipoprotein lipase recruitment rate
Study
ratn: not reported in source
Perfused rat hearts
Outcome group
Lipids · Cardiovascular
Studied dose
0.5 mmol/LAs given in this study (rat).
Source sentences
Summary
After heparin pretreatment, the rate of recruitment of LPL to the cardiac endothelium was increased by AICAR (P < .05) but not by high-dose metformin.
1 context sentence(design, population, supporting numbers)
Summary · context
Control, metformin-treated, and 5-amino-imidazole-4-carboxamide riboside (AICAR)-treated (0.5 mmol/L) ex vivo hearts were perfused to investigate uptake of triacylglycerol and cardiac LPL activity.
Report a problemFND-2015348806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.